Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer.
CONCLUSIONS: The safety profile of two capecitabine formulations - innovative and generic- appears to be associated with the chemotherapy scheme employed, and not the drug itself. Most palmar- plantar erythrodysesthesia for monotherapy is likely due to the higher dose of capecitabine used in said scheme. The increase in neurotoxicity, thrombocytopenia and neutropenia for XELOX is probably due to cumulative toxicity of two antineoplastic drugs.
PMID: 31469628 [PubMed - in process]
Source: Farmacia Hospitalaria - Category: Drugs & Pharmacology Authors: Sánchez-Gundín J, Torres-Suárez AI, Fernández-Carballido AM, Barreda-Hernández D Tags: Farm Hosp Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Colorectal Cancer | Drugs & Pharmacology | Neurology | Statistics | Study | Thrombocytopenia | Toxicology | Xeloda